Published in Am J Obstet Gynecol on February 01, 1991
The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer (1996) 1.51
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer (2007) 1.36
Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. BMC Cancer (2010) 1.31
Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol Ther (2011) 1.08
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer (1999) 1.05
Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa"). Br J Cancer (2002) 1.05
Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer (1995) 1.01
The G protein-coupled estrogen receptor 1 (GPER/GPR30) does not predict survival in patients with ovarian cancer. J Ovarian Res (2012) 1.00
Nuclear entry of activated MAPK is restricted in primary ovarian and mammary epithelial cells. PLoS One (2010) 0.97
c-erbB-3 protein expression in ovarian tumours. Br J Cancer (1995) 0.97
GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer. J Ovarian Res (2012) 0.94
The detection, treatment, and biology of epithelial ovarian cancer. J Ovarian Res (2010) 0.92
Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay. Br J Cancer (1992) 0.92
EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem (2012) 0.90
Epidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagen. Mol Cancer Res (2009) 0.89
Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs. Cancer Lett (2008) 0.89
Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci U S A (1994) 0.88
HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy. J Cancer (2011) 0.86
Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol (1994) 0.85
Betacellulin induces Slug-mediated down-regulation of E-cadherin and cell migration in ovarian cancer cells. Oncotarget (2016) 0.81
Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma. Onco Targets Ther (2013) 0.81
Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer. J Steroid Biochem Mol Biol (2014) 0.81
Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway. Reprod Biol Endocrinol (2010) 0.78
Absence of constitutive EGF receptor activation in ovarian cancer cell lines. Br J Cancer (1996) 0.77
Lysine-specific demethylase 1 mediates epidermal growth factor signaling to promote cell migration in ovarian cancer cells. Sci Rep (2015) 0.76
In vitro regulation of sheep ovarian surface epithelium (OSE) proliferation by local ovarian factors. Saudi J Biol Sci (2012) 0.76
Prognostic impact of chromosome aberrations in ovarian cancer. Br J Cancer (1992) 0.76
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics (1988) 70.41
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med (1996) 11.72
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med (1999) 9.16
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med (1983) 8.82
Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest (1981) 6.89
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med (1996) 5.56
The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod (1989) 4.13
Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A (2000) 3.61
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst (1996) 3.53
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother (1996) 3.20
Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats. Hum Mol Genet (2000) 3.17
Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol (1983) 2.90
Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer (1995) 2.64
Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res (1990) 2.55
Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature (1994) 2.53
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood (1995) 2.43
Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol (1992) 2.43
Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res (1986) 2.37
A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol Oncol (2000) 2.34
Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol (1983) 2.33
Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med (1995) 2.33
Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol (1999) 2.25
Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res (1991) 2.20
BCG and cancer (first of two parts). N Engl J Med (1974) 2.13
Acquired cellular immunity: extracellular killing of Listeria monocytogenes by a product of immunologically activated macrophages. Cell Immunol (1974) 2.07
Hyperbaric oxygen improves tumor radiation response significantly more than carbogen/nicotinamide. Radiat Res (1997) 2.02
Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res (1986) 2.01
NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A (1999) 2.00
Cost-effectiveness of treatment of early stage endometrial cancer. Gynecol Oncol (1999) 1.99
Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood (1999) 1.85
Cutaneous basophil hypersensitivity. 3. Participation of the basophil in hypersensitivity to antigen-antibody complexes, delayed hypersensitivity and contact allergy. Passive transfer. J Immunol (1971) 1.84
Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res (1984) 1.83
Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene (1999) 1.81
Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res (2001) 1.77
Communication skills training in oncology. Description and preliminary outcomes of workshops on breaking bad news and managing patient reactions to illness. Cancer (1999) 1.73
Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst (1993) 1.71
Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med (1989) 1.69
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med (1988) 1.67
Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol (1996) 1.66
BCG and cancer. N Engl J Med (1974) 1.66
Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol (1999) 1.66
CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol (1984) 1.61
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol (1993) 1.61
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst (1993) 1.60
Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol (1984) 1.60
p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol (1996) 1.59
The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol (1990) 1.59
HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene (2006) 1.58
PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res (1998) 1.58
The effect of LPS on expression of the early "competence" genes JE and KC in murine peritoneal macrophages. J Immunol (1987) 1.50
A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol (1993) 1.44
The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res (1999) 1.43
Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model. Acta Oncol (1998) 1.43
Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ (1994) 1.42
Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy studies VIII, IX, and X. J Clin Oncol (1991) 1.42
Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res (1991) 1.41
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol (1988) 1.40
Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J Natl Cancer Inst (1994) 1.39
Defining practice patterns in gynecologic oncology to prevent pulmonary embolism and deep venous thrombosis. Gynecol Oncol (2007) 1.36
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol (1999) 1.36
Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene (1997) 1.34
Improving physician-patient communication in cancer care: outcome of a workshop for oncologists. J Cancer Educ (1997) 1.32
Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol (2000) 1.32
Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol (1985) 1.32
Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol (1984) 1.30
Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res (1986) 1.29
Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer (1995) 1.29
Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. Cancer Res (1996) 1.28
Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol (1999) 1.28
Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol (1995) 1.27
The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol (2000) 1.27
Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol (1997) 1.26
Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res (1993) 1.26
A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. Hum Mol Genet (1994) 1.25
Mucin gene expression in ovarian cancers. Cancer Res (1998) 1.24
Treatment of murine peritoneal macrophages with bacterial lipopolysaccharide alters expression of c-fos and c-myc oncogenes. J Immunol (1986) 1.24
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood (1994) 1.22
Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood (1992) 1.21
Heterogeneity of the cellular immune response. II. The role of adjuvant, lymphocyte stimulation in cutaneous basophil hypersensitivity. J Exp Med (1971) 1.21